Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Database analyses of predictors of resistance.

Sabin C.

In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 14.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.
4.

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR.

PLoS Med. 2006 Sep;3(9):e356.

5.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607
6.

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team.

AIDS Patient Care STDS. 2008 Jul;22(7):545-52. doi: 10.1089/apc.2007.0200.

7.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

8.

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, Holte SE, De Vange SM, Pawluk DM, Melvin AJ, Lewis PF, Heath LM, Beck IA, Mahalanabis M, Naugler WE, Tobin NH, Mullins JI.

J Virol. 2003 May;77(10):5721-30.

9.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
10.
11.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.

PMID:
10789605
12.

Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.

Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D.

Eur J Med Res. 2004 May 28;9(5):273-8.

PMID:
15257882
13.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

14.
15.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

PMID:
15714420
16.

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.

Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort.

J Infect Dis. 2002 Oct 15;186(8):1086-91. Epub 2002 Sep 30.

PMID:
12355358
17.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
19.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
20.

Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.

Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Traore M, Sylla M, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Jan;65(1):118-24. doi: 10.1093/jac/dkp412.

PMID:
19933171

Supplemental Content

Support Center